Literature DB >> 28675689

Psoas as a sentinel muscle for sarcopenia: a flawed premise.

Vickie E Baracos1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28675689      PMCID: PMC5566635          DOI: 10.1002/jcsm.12221

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


× No keyword cloud information.
Loss of mass and functional capacity of skeletal muscle is a major cause of morbidity in older individuals as well as in patients affected by a host of acute and chronic conditions including infectious disease, endocrine and metabolic disorders, organ dysfunction, immunological disease, vascular diseases, haematological disorders, and malignancies. Quantitative approaches are required to diagnose and study this muscle loss, and these are represented in the literature predominantly by dual energy X‐ray (DXA), computed tomography (CT), and magnetic resonance imaging.1 Total appendicular skeletal muscle by DXA has been considered the standard quantitative measure1 and appears in nearly 500 publications. The application of CT has recently been popularized in patients who had an indication for CT scan as part of their standard medical care. The methods cited above are subject to the limitation that they are not typically amenable to the quantification of whole body muscle mass, for different reasons. DXA is limited to muscle in the limbs, and clinical CT scans are rarely of the whole body. Within these restrictions, effort is taken to measure as much, if not all of the muscle, to fully represent this organ system. Literature on sarcopenia does not focus on specific individual muscles, rather the systemic loss of muscle, and its impact on overall function2, 3 is highlighted. While the CT approach is not yet set to internationally accepted standards, the majority of researchers adopted quantification of total lumbar muscle cross‐sectional area (CSA) because this region is the object of diagnostic imaging in multiple illnesses and this area of the body includes a diverse representation of muscles (psoas, erector spinae, quadratus lumborum, transverse abdominis, external and internal obliques, and rectus abdominus). Lumbar muscle area is also reasonably well correlated with whole body muscle mass.4, 5 A single‐muscle approach to the diagnosis of clinically important depletion of skeletal muscle is a recent trend in the literature on CT‐defined muscle quantification. The single muscle is most often the psoas major and occasionally adductor pollicis, pectoralis, or masseter. Single muscle studies represent a minority (~6%) of quantitative studies of muscle mass, and the vast majority of scholarly works on sarcopenia does not contain any suggestion that a single muscle would serve as a sentinel. The premise that psoas should be selected over all other individual muscles, muscle groups, and total muscle mass has not been discussed in the literature nor has any validation been conducted. The choice of psoas is merely stated to be ‘simple and convenient’6 to measure. The article by Rutten et al. in this edition of JCSM7 provides a quantitative comparison of total lumbar muscle area with the psoas area. Data are from patients with ovarian cancer, but the findings may have broader implication. The weaknesses that these authors observe for the psoas‐only approach include its very low proportion of total trunk muscles (<10%), high measurement error, and weak correlation of psoas area with total lumbar muscle area. Psoas area change over time showed a large variance and was unrelated to the clinical outcome of overall survival. A method of imputation of psoas area from measures of its length and width was particularly disastrous in terms of its poor correlation with psoas area and the high inconsistency of measures between observers. This muscle is not symmetrical in shape, and such methods would seem unlikely to be reliable. By a variety of quantitative indices, psoas failed all tests of technical and clinical merits for the assessment of systemic muscle wasting in this patient population. A rabble of disparate measurements and reporting is found in the publications concerning psoas muscle sarcopenia. Psoas is represented variously by its unidimensional thickness, its CSA in unadjusted cm2, CSA normalized to patient height2, CSA normalized to body surface area, or CSA normalized to the area of the adjacent vertebral body; occasionally, the volume of the entire muscle has been reported. Psoas area is often measured at a standard lumbar vertebral landmark (L3 or L4), but sometimes, unreliable soft tissue landmarks such as the umbilicus have been used. The literature contains no justification (or reconciliation) of these disparate approaches. The resulting data cannot be aggregated, nor can it be compared with the larger literature in which the accepted basis for normalization of muscle mass is by the individual subject's height2. Quantitative data on psoas have been related to a variety of clinical outcomes, with the overall concept that some threshold for low psoas amount would predict morbidity or mortality; however, because such threshold values are reported in disparate units of measure, no general conclusions can be reached. Muscles have specific functions. Psoas is the main flexor of the hip and also provides postural support of the lumbar spine, sacroiliac, and hip joints. The fibre type is mixed (40% type I, 50% type IIa, and 10% type IIx) with the 60:40 predominance of fast fibres providing for psoas dynamic and postural functions.8, 9 However, as Rutter et al.7 point out, a large theme in literature concerning the psoas relates to spinal pathology. Localized psoas atrophy occurs with spinal injury, spinal deformity, spinal degeneration, specific diseases of the spine, and low back pain of known and unknown aetiologies. These conditions are extremely common in older adults that researchers are typically studying using CT. e.g. Low back pain is the fifth most common reason for all physician visits in the USA.10 The worldwide lifetime prevalence of low back pain is 84%.11 Osteoarthritis of the hip, another prevalent condition in older adults, associates with atrophy and fatty degeneration of the psoas. 12 These demographics suggest a high likelihood of localized psoas atrophy, independent of the behaviour of other muscles and muscle groups, and undermine the idea of its utility as a sentinel muscle. In the end, it is not surprising that the notion of a single sentinel muscle for the diagnosis of sarcopenia is not proposed by any expert group,1, 2 as it would be difficult to claim that any one muscle is representative. While it is hoped that the quantification of human skeletal muscle mass might be made more accessible and rapid, this aim may be more realistically be achieved by automation of the total muscle segmentation in CT images.13

Conflict of interest

None declared.
  15 in total

Review 1.  Non-specific low back pain.

Authors:  Federico Balagué; Anne F Mannion; Ferran Pellisé; Christine Cedraschi
Journal:  Lancet       Date:  2011-10-06       Impact factor: 79.321

2.  Morphologic change of the psoas muscle as a surrogate marker of sarcopenia and predictor of complications after colorectal cancer surgery.

Authors:  Marie Hanaoka; Masamichi Yasuno; Megumi Ishiguro; Shinichi Yamauchi; Akifumi Kikuchi; Michiyo Tokura; Toshiaki Ishikawa; Eiji Nakatani; Hiroyuki Uetake
Journal:  Int J Colorectal Dis       Date:  2017-02-11       Impact factor: 2.571

3.  Immunohistochemical analysis of the human psoas major muscle with regards to the body side and aging.

Authors:  Juraj Arbanas; Gordana Starcevic Klasan; Marina Nikolić; Olga Cvijanović; Daniela Malnar
Journal:  Coll Antropol       Date:  2010-04

4.  Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey.

Authors:  L G Hart; R A Deyo; D C Cherkin
Journal:  Spine (Phila Pa 1976)       Date:  1995-01-01       Impact factor: 3.468

5.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.

Authors:  Marina Mourtzakis; Carla M M Prado; Jessica R Lieffers; Tony Reiman; Linda J McCargar; Vickie E Baracos
Journal:  Appl Physiol Nutr Metab       Date:  2008-10       Impact factor: 2.665

6.  Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.

Authors:  Darcy Quinn Holt; Boyd Josef Gimnicher Strauss; Kenneth K Lau; Gregory Thomas Moore
Journal:  Scand J Gastroenterol       Date:  2016-03-22       Impact factor: 2.423

7.  Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Authors:  Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-08-03       Impact factor: 12.910

8.  Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004.

Authors:  John A Batsis; Laura K Barre; Todd A Mackenzie; Sarah I Pratt; Francisco Lopez-Jimenez; Stephen J Bartels
Journal:  J Am Geriatr Soc       Date:  2013-05-06       Impact factor: 7.538

9.  Psoas as a sentinel muscle for sarcopenia: a flawed premise.

Authors:  Vickie E Baracos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-07-03       Impact factor: 12.910

10.  Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer.

Authors:  Iris J G Rutten; Jorne Ubachs; Roy F P M Kruitwagen; Regina G H Beets-Tan; Steven W M Olde Damink; Toon Van Gorp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-05-16       Impact factor: 12.910

View more
  40 in total

1.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 2.  Total-Body PET Imaging of Musculoskeletal Disorders.

Authors:  Abhijit J Chaudhari; William Y Raynor; Ali Gholamrezanezhad; Thomas J Werner; Chamith S Rajapakse; Abass Alavi
Journal:  PET Clin       Date:  2021-01

3.  Impact of Body Mass Index and Sarcopenia on Short- and Long-Term Outcomes After Esophageal Cancer Surgery: An Observational Study.

Authors:  Go Wun Kim; Jae-Sik Nam; Mohd Fitry Bin Zainal Abidin; Seon-Ok Kim; Ji-Hyun Chin; Eun-Ho Lee; In-Cheol Choi
Journal:  Ann Surg Oncol       Date:  2022-05-27       Impact factor: 4.339

4.  MRI biomarker of muscle composition is associated with severity of pelvic organ prolapse.

Authors:  L Neshatian; J P Lam; B H Gurland; T Liang; L Becker; V R Sheth
Journal:  Tech Coloproctol       Date:  2022-06-21       Impact factor: 3.699

Review 5.  Sarcopenia in patients with colorectal cancer: A comprehensive review.

Authors:  Omar Vergara-Fernandez; Mario Trejo-Avila; Noel Salgado-Nesme
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

Review 6.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

Review 7.  The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review.

Authors:  Paolo Bossi; Paolo Delrio; Annalisa Mascheroni; Michela Zanetti
Journal:  Nutrients       Date:  2021-06-09       Impact factor: 5.717

8.  Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers.

Authors:  Tomoyuki Yoshikawa; Morikazu Miyamoto; Tadashi Aoyama; Hiroko Matsuura; Hideki Iwahashi; Hiroki Ishibashi; Soichiro Kakimoto; Takahiro Sakamoto; Kazuki Takasaki; Jin Suminokura; Hitoshi Tsuda; Hiroyuki Kawaguchi; Aihide Yoshino; Masashi Takano
Journal:  Mol Clin Oncol       Date:  2021-07-01

9.  Psoas as a sentinel muscle for sarcopenia: a flawed premise.

Authors:  Vickie E Baracos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-07-03       Impact factor: 12.910

10.  Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer.

Authors:  Moon Hyung Choi; Seung Bae Yoon; Kyungjin Lee; Meiying Song; In Seok Lee; Myung Ah Lee; Tae Ho Hong; Myung-Gyu Choi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-02-05       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.